These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36541643)

  • 1. Gut microbiota alterations after switching from a protease inhibitor or efavirenz to raltegravir in a randomized, controlled study.
    Hanttu AM; Pekkala S; Satokari R; Hartikainen AK; Arkkila P; Pietiläinen KH; Sutinen JP
    AIDS; 2023 Feb; 37(2):323-332. PubMed ID: 36541643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
    Macías J; Mancebo M; Merino D; Téllez F; Montes-Ramírez ML; Pulido F; Rivero-Juárez A; Raffo M; Pérez-Pérez M; Merchante N; Cotarelo M; Pineda JA;
    Clin Infect Dis; 2017 Sep; 65(6):1012-1019. PubMed ID: 28903510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir.
    Hanttu A; Vuoti S; Kivelä P; Arkkila P; Lundbom N; Hakkarainen A; Lundbom J; Lehtimäki T; Viskari H; Lehtinen V; Pietiläinen KH; Sutinen J
    AIDS Patient Care STDS; 2021 Sep; 35(9):335-341. PubMed ID: 34524919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.
    Vieira MC; Kumar RN; Jansen JP
    HIV Clin Trials; 2011; 12(4):175-89. PubMed ID: 22044854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine.
    Ray S; Narayanan A; Giske CG; Neogi U; Sönnerborg A; Nowak P
    ACS Infect Dis; 2021 May; 7(5):1104-1115. PubMed ID: 33346662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
    Date AA; Shibata A; Goede M; Sanford B; La Bruzzo K; Belshan M; Destache CJ
    Antiviral Res; 2012 Dec; 96(3):430-6. PubMed ID: 23041201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adiponectin and the steatosis marker Chi3L1 decrease following switch to raltegravir compared to continued PI/NNRTI-based antiretroviral therapy.
    Offor O; Utay N; Reynoso D; Somasunderam A; Currier J; Lake J
    PLoS One; 2018; 13(5):e0196395. PubMed ID: 29746485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).
    Nguyen A; Calmy A; Delhumeau C; Mercier I; Cavassini M; Mello AF; Elzi L; Rauch A; Bernasconi E; Schmid P; Hirschel B
    AIDS; 2011 Jul; 25(12):1481-7. PubMed ID: 21593661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens.
    Cook PP; Stang AT; Walker LR; Akula SM; Cook FJ
    South Med J; 2016 Nov; 109(11):712-717. PubMed ID: 27812717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
    Taramasso L; Tatarelli P; Ricci E; Madeddu G; Menzaghi B; Squillace N; De Socio GV; Martinelli C; Gulminetti R; Maggi P; Orofino G; Vichi F; Di Biagio A; Bonfanti P;
    BMC Infect Dis; 2018 Jul; 18(1):357. PubMed ID: 30064371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Integrase Inhibition Compared With Nonnucleoside Inhibition on HIV Reservoirs in Lymphoid Tissues.
    Rothenberger M; Nganou-Makamdop K; Kityo C; Ssali F; Chipman JG; Beilman GJ; Hoskuldsson T; Anderson J; Jasurda J; Schmidt TE; Calisto SP; Pearson H; Reimann T; David C; Perkey K; Southern P; Wietgrefe S; Helgeson E; Reilly C; Haase AT; Douek DC; Fletcher CV; Schacker TW
    J Acquir Immune Defic Syndr; 2019 Jul; 81(3):355-360. PubMed ID: 31192893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
    Andrade A; Rosenkranz SL; Cillo AR; Lu D; Daar ES; Jacobson JM; Lederman M; Acosta EP; Campbell T; Feinberg J; Flexner C; Mellors JW; Kuritzkes DR;
    J Infect Dis; 2013 Sep; 208(6):884-91. PubMed ID: 23801609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
    Kelesidis T; Tran TT; Stein JH; Brown TT; Moser C; Ribaudo HJ; Dube MP; Murphy R; Yang OO; Currier JS; McComsey GA
    Clin Infect Dis; 2015 Aug; 61(4):651-60. PubMed ID: 25904376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch to raltegravir decreases soluble CD14 in virologically suppressed overweight women: the Women, Integrase and Fat Accumulation Trial.
    Lake JE; McComsey GA; Hulgan T; Wanke CA; Mangili A; Walmsley SL; Stramotas SA; Tracy R; Currier JS
    HIV Med; 2014 Aug; 15(7):431-41. PubMed ID: 24506429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch to efavirenz in a protease inhibitor-containing regimen.
    Knechten H; Stürner KH; Höhn C; Braun P
    HIV Clin Trials; 2001; 2(3):200-4. PubMed ID: 11590528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
    BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.
    McComsey GA; Moser C; Currier J; Ribaudo HJ; Paczuski P; Dubé MP; Kelesidis T; Rothenberg J; Stein JH; Brown TT
    Clin Infect Dis; 2016 Apr; 62(7):853-62. PubMed ID: 26797215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.